What Is Cortical Dysplasia and How Is It Treated?

Cortical dysplasia is a brain malformation in which neurons in the outer layer of the brain, the cortex, fail to organize properly during fetal development. The result is a patch of structurally abnormal tissue that disrupts normal electrical signaling and, in most cases, triggers seizures that are difficult to control with medication alone. First described as a distinct condition in 1971, focal cortical dysplasia (FCD) is now recognized as one of the most common causes of drug-resistant epilepsy in children and a frequent finding in adults who undergo epilepsy surgery.¹ Treatment ranges from anti-seizure medications and dietary therapies to surgical removal of the abnormal tissue, with the right approach depending heavily on the type, location, and genetic underpinnings of the lesion.

What Goes Wrong During Brain Development

During normal brain development, neurons are born deep in the brain and migrate outward to form the cortex in an orderly, layered structure. In cortical dysplasia, something disrupts that migration or the final positioning of those neurons. The affected patch ends up with jumbled layers, abnormally large cells, or both. Because the cortex handles everything from movement and sensation to language and memory, even a small area of disorganized tissue can act as a persistent source of abnormal electrical activity.

Research over the past two decades has traced much of this disruption, particularly in the more severe forms, to overactivity in a cellular signaling pathway called mTOR. This pathway normally helps regulate cell growth and division. When genetic mutations cause it to become hyperactive in a localized area of developing brain tissue, cells grow too large and land in the wrong positions.² These mutations are typically somatic, meaning they arise spontaneously in a small number of cells during development rather than being inherited from a parent. Researchers have identified mutations in genes like TSC1 and TSC2 in resected FCD tissue, confirming that localized mTOR hyperactivation can produce these focal malformations.³

Types of Focal Cortical Dysplasia

Not all cortical dysplasia looks or behaves the same. The International League Against Epilepsy (ILAE) established a classification system that divides FCD into three main types, each with subtypes. Understanding which type a person has matters because it influences how well the lesion shows up on imaging, how seizures behave, and how likely surgery is to succeed.

FCD Type I: The cortex has abnormal layering but the individual neurons look relatively normal. Type Ia involves disrupted vertical organization, while Type Ib involves disrupted horizontal organization. These lesions tend to be subtle on MRI and can affect one or more lobes.
FCD Type II: The cortex is disorganized and contains clearly abnormal cells. Type IIa has dysmorphic neurons, which are abnormally large and misshapen. Type IIb adds balloon cells, distinctive swollen cells that are a hallmark of mTOR pathway involvement. Type II is diagnosed only when it occurs as an isolated lesion, not alongside another brain abnormality.
FCD Type III: The cortical dysplasia appears next to another brain lesion. Type IIIa occurs alongside hippocampal sclerosis, IIIb alongside a brain tumor, IIIc alongside a vascular malformation, and IIId alongside damage from early-life injury such as trauma, stroke, or infection.

Type II tends to cause the most severe clinical symptoms and usually appears in childhood, with a predilection for the frontal lobes.⁴ It is also the type most closely linked to mTOR pathway mutations and the one first described by David Taylor in 1971.¹ The dysmorphic neurons characteristic of Type II are the major histopathological feature, though their exact role in generating seizures is still being studied.⁵

How Cortical Dysplasia Is Diagnosed

Seizures are the most common symptom that leads to a diagnosis. The type of seizure depends on where the dysplasia sits in the brain: a lesion in the motor cortex may cause rhythmic jerking of a limb, while one in the temporal lobe may produce episodes of staring, confusion, or unusual sensations. Some people have seizures from infancy, while others may not develop them until adolescence or adulthood.

MRI is the first-line imaging tool. In Type II FCD, radiologists look for a cluster of specific signs: cortical thickening, blurring of the boundary between gray and white matter, abnormal signal in the cortex and the white matter beneath it, and the “transmantle sign,” a funnel-shaped streak of abnormal signal extending from the cortex toward the ventricle.⁶ Higher-strength MRI scanners improve detection of these features.

The challenge is that many FCDs, especially Type I and Type III, are invisible or barely visible on MRI. In one study, standard MRI detected FCD in only about 20% of patients. PET scanning, which measures metabolic activity in the brain, picked up the lesion in over 93% of cases. The gap was most dramatic in Type IIIa, where MRI found the lesion in fewer than 6% of patients but PET identified it in nearly 89%.⁷ For this reason, epilepsy centers often combine MRI with PET and sometimes with other tools like magnetoencephalography (MEG) to pin down the seizure source before planning treatment.

Why Seizures Are Often Hard to Control With Medication

Anti-seizure medications are the first treatment tried, and they work well enough for many types of epilepsy. In FCD-related epilepsy, though, the structural abnormality keeps generating seizures no matter how aggressively the drugs are adjusted. The abnormal tissue itself is the problem, and medication can only suppress the electrical storms it produces rather than fix the underlying architecture. A significant proportion of people with FCD continue to have seizures despite trying multiple medications.⁸ This drug resistance is what drives the search for surgical and other interventions.

Surgery as the Primary Treatment for Drug-Resistant FCD

When seizures do not respond to medication, surgical removal of the dysplastic tissue is the most effective treatment available. Across studies, between 50% and 75% of patients are seizure-free two years after surgery, and long-term freedom tends to remain stable after that.⁹ The biggest predictor of success is completeness of resection. In one pediatric study, 88% of patients whose MRI-visible lesion was completely removed achieved the best possible outcome, compared to only a third of those with incomplete removal.¹⁰

Complete removal is easier said than done. The boundary of dysplastic tissue is often poorly defined, and the abnormal region frequently extends beyond what MRI shows.¹¹ That is why preoperative mapping with multiple imaging methods and sometimes invasive electrode monitoring is so important. Surgeons need to know not just where the lesion is, but exactly how far the seizure-generating zone extends and whether it overlaps with brain areas responsible for movement, speech, or vision. When the dysplasia sits in or near eloquent cortex, a complete resection may not be possible without unacceptable neurological deficits.

Minimally Invasive Surgical Alternatives

For patients whose FCD is small, deep-seated, or located near critical brain areas, open surgery may not be ideal. Two minimally invasive techniques have gained ground in recent years: laser interstitial thermal therapy (LITT) and radiofrequency thermocoagulation (RFTC). Both destroy the abnormal tissue using heat delivered through small probes, avoiding the need for a large craniotomy.

A systematic review comparing the two approaches in FCD patients found that LITT produced seizure freedom in about 59% of cases and RFTC in about 52%, with no significant difference between them. Both methods achieved at least a 50% seizure reduction in roughly 90% of patients.¹² LITT patients are typically discharged the day after the procedure.¹³ Complication rates were not significantly different between the two techniques, though the overall numbers studied remain relatively small. When a minimally invasive approach does not achieve seizure control, patients can still proceed to open surgery.

Neurostimulation for Seizures That Cannot Be Removed

Some people with FCD are not candidates for any kind of resection or ablation, either because the lesion overlaps too much with essential brain functions or because the seizure focus cannot be precisely localized. In these cases, neurostimulation devices offer a way to reduce seizure frequency without removing tissue.

Three main approaches are used in drug-resistant epilepsy. Vagus nerve stimulation (VNS) delivers intermittent electrical pulses to the vagus nerve in the neck and reduces seizures in roughly half of patients. Responsive neurostimulation (RNS) is a closed-loop device implanted in the skull that monitors brain activity and delivers targeted stimulation when it detects the electrical signature of an approaching seizure, making it particularly useful when the seizure focus lies in brain regions that cannot be safely removed. Deep brain stimulation (DBS) targets specific nuclei in the thalamus, with the anterior nucleus being the primary target for focal epilepsy.¹⁴ None of these devices are specific to FCD; they are tools for drug-resistant epilepsy in general. They rarely eliminate seizures entirely but can significantly reduce their frequency and severity.

The Ketogenic Diet as a Treatment Tool

The ketogenic diet, a high-fat, very-low-carbohydrate regimen that shifts the brain’s energy metabolism, has a long track record in pediatric epilepsy. It has also been studied specifically in children with cortical malformations, including FCD. In one study of children with focal cortical malformations, about 62% had their seizure frequency cut by more than half within three months, and roughly 45% became seizure-free during that period. Among those who achieved full seizure control at three months, about three-quarters maintained it through two years on the diet.¹⁵

A separate two-center study found that 44% of children with cortical malformation-related epilepsy achieved at least a 50% seizure reduction on the diet.¹⁶ Researchers have wondered whether the diet’s effectiveness might depend on whether the underlying FCD involves mTOR pathway mutations, since the diet has some overlapping metabolic effects with mTOR inhibitors. A small study found that children with detectable mTOR mutations responded somewhat more often than those without, but the difference was not statistically significant.¹⁷ The ketogenic diet is rarely a standalone solution for FCD, but it can serve as a bridge therapy while awaiting surgery or as an adjunct when surgery is not feasible.

Targeted Drug Therapy and the mTOR Connection

Because mTOR pathway overactivation drives much of the abnormal cell growth in FCD Type II, researchers have tested whether mTOR-inhibiting drugs like everolimus could reduce seizures. Everolimus is already approved for seizure control in tuberous sclerosis complex (TSC), a genetic condition that shares the same underlying mTOR mechanism.¹⁸

The results in FCD so far have been mixed. A clinical trial comparing everolimus to placebo in FCD Type II patients found no significant overall difference in seizure reduction between the two groups. However, the responses varied depending on genetics: three patients who carried a specific mutation in the MTOR gene or had no detectable genetic abnormality achieved seizure freedom with everolimus, while none of the patients with mutations in other genes did.¹⁹ A separate pilot study examining everolimus given before epilepsy surgery found no adverse events and a trend toward reduced mTOR signaling in the resected tissue.²⁰

The emerging picture is that mTOR inhibitors may help a subset of FCD patients, particularly those whose specific mutation directly activates the mTOR protein, but are unlikely to work as a blanket treatment for all FCD. Genetic testing of resected or biopsied tissue is increasingly important for identifying who might benefit. The somatic nature of the mutations, present only in the affected brain tissue and not in blood, makes routine genetic screening challenging, but techniques for detecting these low-frequency mutations are improving.

Cognitive Effects and the Case for Early Intervention

FCD affects more than just seizure frequency. Children with FCD commonly experience delays in cognitive development, difficulties with memory, attention, language, and executive function. These problems stem from a combination of the structural abnormality itself, the disruptive effects of frequent seizures on the developing brain, and the side effects of anti-seizure medications.²¹

The age at which epilepsy begins appears to shape cognitive outcomes. Research suggests that children whose seizures start before age six, during a critical window of brain plasticity, face different neurocognitive profiles than those whose epilepsy begins later.²² This creates a paradox: the youngest children are the most vulnerable to seizure-related cognitive harm, but they also have the greatest capacity for recovery if the seizures are stopped.

Studies evaluating cognitive outcomes after epilepsy surgery in children with FCD have found that about a quarter of children show a clinically meaningful improvement of 10 or more IQ points after surgery, with the greatest gains seen in children who had epileptic encephalopathy before the operation.²¹ Delayed cognitive development and poor quality of life are common in children living with uncontrolled FCD-related seizures, and evidence supports the idea that earlier surgical intervention, when indicated, gives the best chance not just for seizure control but for cognitive catch-up and improved quality of life.²³

What Neuropsychological Testing Involves

Before and after epilepsy surgery, children and adults with FCD typically undergo detailed neuropsychological assessments. These evaluations cover intelligence, language, visual-motor skills, memory, attention, executive function, processing speed, and psychosocial functioning.²⁴ The purpose is twofold: to understand the patient’s baseline cognitive strengths and vulnerabilities before surgery, and to track whether surgery improves, preserves, or harms any of these functions afterward.

Testing is especially important when the FCD sits near regions controlling language or memory. For frontal lobe FCD, assessments focus on executive function, working memory, and processing speed, since these are the abilities most at risk from both the lesion and any surgical intervention.²⁵ For families navigating an FCD diagnosis in a child, these evaluations provide concrete data about what the child needs in terms of educational support and therapy, both before and after any procedure.

Genetic Testing and Its Practical Limits

Genetic testing in FCD occupies an unusual space. Unlike conditions caused by inherited mutations that show up in every cell, the mutations driving most FCD are somatic and confined to the affected brain tissue. A standard blood test will usually come back normal. Detecting the causative mutation typically requires analysis of surgically resected tissue, which means genetic confirmation often comes after treatment rather than before it.²⁶

For families, this has practical implications. Parents of a child with isolated FCD sometimes worry about the risk of the same condition occurring in another child. Because the mutations are somatic and not present in the parents’ DNA, the recurrence risk for siblings is very low. The condition is not inherited in the way single-gene disorders like cystic fibrosis are. That said, rare familial forms of cortical malformations do exist, and genetic counseling can help families understand where their specific situation falls. When a mutation is identified in resected tissue, it can also guide treatment decisions, particularly regarding whether mTOR-targeted drugs might be worth trying if seizures recur after surgery.

Living With FCD When Surgery Is Not an Option

Not everyone with FCD is a surgical candidate, and not every surgery succeeds. For people living with ongoing seizures, management becomes a long-term balancing act of medication combinations, dietary therapy, and possibly neurostimulation. Quality-of-life concerns extend well beyond seizure counts. Unpredictable seizures affect driving, employment, independence, and mental health. Anti-seizure medications carry side effects ranging from drowsiness and weight changes to mood disturbances. Children with uncontrolled seizures may need individualized education plans, occupational therapy, and ongoing developmental monitoring.

The field is moving toward more personalized approaches. As genetic sequencing of resected brain tissue becomes more routine, researchers are building a clearer map of which mutations respond to which treatments. The discovery that FCD sits on a spectrum of mTOR-related conditions, alongside tuberous sclerosis and certain brain tumors, has opened up drug repurposing possibilities that did not exist a decade ago. For now, the core message for patients and families is that FCD-related epilepsy benefits from evaluation at a specialized epilepsy center, where the full range of diagnostic tools and treatment options can be coordinated rather than tried piecemeal.